文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗青少年中重度特应性皮炎:IIa期开放标签试验及III期开放标签扩展研究

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
PubMed 文献 · Br J Dermatol · 2019-10-08

度普利尤单抗呈非线性靶点介导药代动力学,52周耐受性良好,最常见不良事件为鼻咽炎和AD加重;EASI持续改善,第52周分别降低85%(2 mg/kg)和84%(4 mg/kg)。

要点

  • 度普利尤单抗在青少年中呈非线性靶点介导药代动力学,第48周谷浓度2 mg/kg组74±19 mg/L、4 mg/kg组161±60 mg/L。
  • 52周内耐受性良好,最常见TEAE为鼻咽炎(2 mg/kg组41%、4 mg/kg组47%)和AD加重(29%、42%)。
  • 单次给药后第2周EASI即改善,持续治疗至第52周EASI分别降低85%(2 mg/kg)和84%(4 mg/kg)。

核心结论

  • 在青少年中重度AD患者中,度普利尤单抗的药代动力学特征与成人相似,52周安全性和有效性数据支持长期使用。

研究设计与样本

  • 全球多中心IIa期开放标签递增剂量序贯队列研究,联合III期开放标签扩展(OLE)。
  • 36例进入OLE,继续每周2 mg/kg或4 mg/kg度普利尤单抗治疗。
  • 主要终点为度普利尤单抗浓度-时间曲线和治疗中出现的不良事件(TEAE)发生率。

主要发现

  • 度普利尤单抗呈非线性、靶点介导的药代动力学。
  • 第48周(OLE)血清谷浓度均值±SD:2 mg/kg组74±19 mg/L,4 mg/kg组161±60 mg/L。
  • 52周内耐受性良好;最常见TEAE为鼻咽炎(第52周:2 mg/kg组41%,4 mg/kg组47%)和AD加重(29%,42%)。
  • IIa期单次给药后第2周EASI较基线改善:2 mg/kg组平均降低34%±20%,4 mg/kg组降低51%±29%。
  • 持续治疗至第52周EASI进一步改善:2 mg/kg组降低85%±12%,4 mg/kg组降低84%±20%。

关键数值与推荐

  • IIa期给药方案:单次2 mg/kg或4 mg/kg,随后每周同剂量给药4周。
  • OLE继续每周2 mg/kg或4 mg/kg度普利尤单抗治疗。

临床怎么用

  • 52周安全性和有效性数据支持度普利尤单抗用于青少年中重度AD的长期治疗。
  • 数据支持度普利尤单抗与当前标准治疗(外用糖皮质激素)联合使用。

局限性

  • IIa期及OLE均为开放标签设计,未设安慰剂对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD). Dupilumab significantly improved AD signs/symptoms in a 16-week, randomised, placebo-controlled phase III trial in adolescents (NCT03054428). OBJECTIVES: To characterize the pharmacokinetics of dupilumab, and long-term safety and efficacy in adolescents. METHODS: This was a global, multicentre, phase IIa, open-label, ascending-dose, sequential cohort study with a phase III open-label extension (OLE) in adolescents with moderate-to-severe AD. In the phase IIa study, patients received one dupilumab dose (2 mg kg-1 or 4 mg kg-1 ) and 8 weeks of pharmacokinetic sampling. Thereafter, patients received the same dose weekly for 4 weeks, with 8-week safety follow-up. Patients then enrolled in the OLE, continuing 2 mg kg-1 or 4 mg kg-1 dupilumab weekly. Primary end points were dupilumab concentration-time profile and incidence of treatment-emergent adverse events (TEAEs). Secondary outcomes included Eczema Area and Severity Index (EASI). RESULTS: Forty adolescents received dupilumab in the phase IIa study; 36 enrolled in the OLE. Dupilumab showed nonlinear, target-mediated pharmacokinetics. Mean ± SD trough dupilumab concentrations in serum at week 48 (OLE) were 74 ± 19 mg L-1 and 161 ± 60 mg L-1 for 2 mg kg-1 and 4 mg kg-1 , respectively. Dupilumab was well tolerated over 52 weeks; the most common TEAEs were nasopharyngitis (week 52: 41% [2 mg kg-1 ], 47% [4 mg kg-1 ]) and AD exacerbation (29%, 42%). After one dupilumab dose in the phase IIa study, EASI improved from baseline to week 2 [mean ± SD reduction -34% ± 20% (2 mg kg-1 ) and -51% ± 29% (4 mg kg-1 )]. With continuing treatment, EASI scores improved further [week 52: -85% ± 12% (2 mg kg-1 ) and -84% ± 20% (4 mg kg-1 )]. CONCLUSIONS: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candidates for systemic therapy (European Union). A 16-week, randomized, placebo-controlled phase III trial in adolescents demonstrated significant improvements in AD signs/symptoms with an acceptable safety profile. What does this study add? These studies demonstrate the long-term safety and efficacy of dupilumab in adolescents with moderate-to-severe AD for up to 52 weeks of treatment, thus extending and reinforcing the findings from the 16-week dupilumab phase III trial. The data from these studies also support the use of dupilumab in combination with current standard of care (topical corticosteroids), which was not evaluated in the 16-week phase III monotherapy trial.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2019. PMID: 31595499. doi:10.1111/bjd.18476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。